Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
BLUEJETNSEBlue Jet Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 6 Jul, 2026 · 14:53 IST

Blue Jet Healthcare FY26 audited results filed; revenue and PAT decline

Revenue DeclineResults View source PDFExplain this filing

BLUEJET · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.5%Reaction day
₹557.85
prior close
₹556.00
announcement price
In-mkt
timing
Nifty Smallcap 250market+0.5%+2.1% vs market
Pharmaceuticals peers, median of 164sector-0.5%+3.0% vs sector

On the reaction day the stock moved 2.1 pts more than Nifty Smallcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.2
10m
-0.0
15m
+0.0
30m
+1.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.5+0.5+2.1-0.5+3.0
Next day
+3.3-0.2+3.5-0.7+4.0
2d
+1.3-2.2+3.5-1.7+3.0
3d
+3.2-0.7+3.9-1.3+4.5
4d
+11.8+0.7+11.1-0.5+12.3
5d
+8.8+1.0+7.8+0.2+8.5
1w
+7.7+0.6+7.2+0.4+7.3
15d
+3.8-1.0+4.7-1.4+5.2
1m
+5.4+2.0+3.4-1.7+7.1
2m
+2.2+2.7-0.5+1.2+1.0
3m
-3.4-0.5-2.9+0.6-3.9
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Blue Jet Healthcare has filed audited standalone results for FY ended March 2026. Revenue from operations fell to Rs 9,047 million from Rs 10,300 million (down about 12%). Profit after tax declined to Rs 2,471 million from Rs 3,052 million (down about 19%). Auditor KKC and Associates gave a clean (unqualified) opinion. Board proposed a final dividend for FY26, subject to shareholder approval at the upcoming AGM. No going concern issues were flagged.

Likely market impact

Revenue and PAT both declined year on year, indicating margin pressure. A clean audit opinion and proposed dividend are supportive; await AGM outcome and consolidated numbers.